CLAIMS:

1. Use of an effective amount of minoxidil for the preparation of a medicament for the treatment or prevention of telogen effluvium in a subject wherein the effective amount of minoxidil is from about 0.1 mg to 0.49 mg, or from about 0.1 mg to 0.4 mg, or from about 0.15 mg to 0.3 mg, or from about 0.2 mg to 0.28 mg, or is about 0.25 mg, or is about 0.24 mg, or is about 0.1 mg.

2. The use according to claim 1, wherein the effective amount is administered daily.

3. The use according to claim 1 or claim 2, wherein the effective amount of minoxidil is about 0.25 mg, or is about 0.5mg, or is about 1mg or is about 2.5 mg daily.

4. The use according to claim 2 or 3, wherein the medicament further comprises: aldosterone antagonist, 5a-reductase inhibitor, non-steroidal antiandrogen drug and/or a steroidal antiandrogen.

5. The use according to any one of claims 1 to 4, wherein the medicament further comprises spironolactone within the range of from about 10 mg to 500 mg, or from about 10 mg to 400 mg, or from about 10 mg to 300 mg, or from about 15 mg to 200 mg, or form about 15 mg to 150 mg, or from about 18 mg to 100 mg, or from about 20 mg to 80 mg, or from about 20 mg to 50 mg, or from about 22 mg to 40 mg, or from about 23 mg to 35 mg, or from about 23 mg to 30 mg, or is about 25 mg.

6. The use according to claim 5, wherein spironolactone is at a concentration of about 25 mg.

7. The use according to any one of claims 1 to 6, wherein the medicament further comprises administering sodium chloride with the range of from about 10 mg to 200 mg, from about 15 mg to 150 mg, from about 15 mg to 125 mg, from about 20 mg to 100 mg, from about 25 mg to 80 mg, from about 30 mg to 70 mg, from about 40 mg to 60 mg, from about 45 mg to 55 mg, or is about 50 mg, or is about 20 mg.

8. The use according to claim 7, wherein sodium chloride at a concentration about 20 mg.

9. The use according to any one of claims 1 to 8, wherein the medicament further comprises one or more of:

(i) finasteride within the range of from about 0.1 mg to 1 mg;

(ii) dutasteride within the range of from about 0.01 mg to 1 mg;

(iii) flutamide within the range of from about 10 mg to 500 mg;

(iv) cyproterone acetate within the rage of from about 1 mg to 100 mg;

(v) bicalutamide within the range of from about 1 mg to 100 mg;

(vi) enzalutamide within the range of from about 1 mg to 100 mg;

(vii) nilutamide within the range of from about 1 mg to 100 mg;

(viii) drosperidone within the range of from about 0.1 mg to 10 mg;

(ix) apalutamide within the range of from about 1 mg to 100 mg; and/or

(x) buseralin within the range of from about 0.1 mg to 10 mg.

10. The use according to any one of claims 1 to 9, wherein the medicament is in the form of a tablet.

11. The use according to any one of claims 1 to 10, wherein the medicament is an oral medicament.

12. Use of about 0.25 mg minoxidil for the preparation of a medicament for the treatment of telogen effluvium in a subject.

13. Use of about 0.5 mg minoxidil for the preparation of a medicament for the treatment of telogen effluvium in a subject.

14. The use of claim 12 or claim 13, wherein the medicament additionally comprises one or more of:

(i) spironolactone within the range of from about 10 mg to 500 mg;

(ii) finasteride within the range of from about 0.1 mg to 1 mg;

(iii) dutasteride within the range of from about 0.01 mg to 1 mg;

(iv) flutamide within the range of from about 10 mg to 500 mg;

(v) cyproterone acetate within the rage of from about 1 mg to 100 mg;

(vi) bicalutamide within the range of from about 1 mg to 100 mg;

(vii) sodium chloride within the rage of from about 10 mg to 200 mg;

(viii) bicalutamide within the range of from about 10 mg to 500 mg;

(iv) enzalutamide within the range of from about 1 mg to 100 mg;

(x) nilutamide within the range of from about 1 mg to 100 mg;

(xi) drosperidone within the range of from about 0.1 mg to 10 mg;

(xii) apalutamide within the range of from about 1 mg to 100 mg; and/or

(xiii) buseralin within the range of from about 0.1 mg to 10 mg.